Metagenomi Therapeutics

MGX

Market cap $45.6M

MGX Hedge Fund Activity: Q1 2026 in Review

48 of the 8,133 institutional investors tracked by Wall St. Rank reported a position in Metagenomi Therapeutics (MGX) for Q1 2026, worth a combined $8.65M — down 21% from $11M a quarter earlier.

Sellers outnumbered buyers: 12 funds closed out of MGX and 5 opened new positions — a net loss of 7 holders — while 15 trimmed existing stakes and 9 added.

The largest buyer was Jacobs Levy Equity Management, opening a new position worth an estimated $594K. The largest seller was Jane Street, cutting an estimated $439K.

• 48 institutional investors held Metagenomi Therapeutics (MGX) as of Q1 2026, down from 56 in Q4 2025.
• Funds reported $8.65M of Metagenomi Therapeutics stock for Q1 2026, down 21% quarter-over-quarter.
• 5 funds opened new Metagenomi Therapeutics positions in Q1 2026 and 12 closed out, a net change of -7 holders.
• The largest Metagenomi Therapeutics buyer in Q1 2026 was Jacobs Levy Equity Management, an estimated $594K added.
• The largest Metagenomi Therapeutics seller in Q1 2026 was Jane Street, an estimated $439K sold.

Based on aggregated 13F filings for Q1 2026.